×
For best experience we recommend to activate Javascript in your browser.
Recombinant RTN4 (Ozanezumab Biosimilar) antibody
The Human Monoclonal anti-RTN4 (Ozanezumab Biosimilar) antibody (ABIN7675800) specifically detects RTN4 (Ozanezumab Biosimilar) in ELISA, BLI, FACS, Func and SPR.
The antibody is reactive with Human samples.
Catalog No. ABIN7675800
$346.15
Plus shipping costs $50.00
1 mg ABIN7581656
100 μg ABIN7675800
1 mg ABIN7581656
100 μg ABIN7675800
Delivery in 10 to 12 Business Days
Quick Overview for Recombinant RTN4 (Ozanezumab Biosimilar) antibody (ABIN7675800)
Target
RTN4 (Ozanezumab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
All hosts for RTN4 (Ozanezumab Biosimilar) antibodies
Human
Clonality
All clonalities for RTN4 (Ozanezumab Biosimilar) antibodies
Monoclonal
Conjugate
All conjugates for RTN4 (Ozanezumab Biosimilar) antibodies
This RTN4 (Ozanezumab Biosimilar) antibody is un-conjugated
Application
ELISA, Bio-Layer Interferometry (BLI), Flow Cytometry (FACS), Functional Studies (Func), Surface Plasmon Resonance (SPR)
Product Details anti-RTN4 (Ozanezumab Biosimilar) Antibody
(hide)
Expression System
CHO Cells
Purpose
Anti-RTN4 / NOGO Reference Antibody (ozanezumab)
Characteristics
Anti-RTN4 / NOGO Reference Antibody (ozanezumab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
Purity
>95 %
Isotype
IgG1
Alternatives
(show)
Application Details
(hide)
Application Notes
Optimal working dilution should be determined by the investigator.
Restrictions
For Research Use only
Handling
(hide)
Format
Lyophilized
Concentration
1 mg/mL
Buffer
25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
Storage
4 °C,-80 °C
Storage Comment
+4°C,-80°C
Target Details for RTN4 (Ozanezumab Biosimilar)
(hide)
Target
RTN4 (Ozanezumab Biosimilar)
Target Type
Biosimilar
Molecular Weight
145.5 kDa
UniProt
Q9NQC3
Recently viewed
(hide)
You are here:
Homepage
Recombinant anti-RTN4 (Ozanezumab Biosimilar) antibody (ABIN7675800)
Chat with us , powered by LiveChat